Hypera S.A. (BVMF:HYPE3)

Brazil flag Brazil · Delayed Price · Currency is BRL
19.76
+0.28 (1.43%)
Mar 28, 2025, 5:07 PM GMT-3
-38.61%
Market Cap 12.50B
Revenue (ttm) 7.44B
Net Income (ttm) 1.33B
Shares Out 632.68M
EPS (ttm) 2.12
PE Ratio 9.31
Forward PE 10.61
Dividend 0.68 (3.45%)
Ex-Dividend Date n/a
Volume 3,101,000
Average Volume 6,563,720
Open 19.48
Previous Close 19.48
Day's Range 19.20 - 20.15
52-Week Range 16.62 - 33.06
Beta 0.45
RSI 53.20
Earnings Date May 8, 2025

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]

Sector Healthcare
Founded 1999
Employees 10,301
Stock Exchange Brazil Stock Exchange
Ticker Symbol HYPE3
Full Company Profile

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.33 billion, a decrease of -19.24%.

Financial Statements

News

There is no news available yet.